UK markets close in 7 hours 27 minutes

ALK-Abelló A/S (ALK-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
154.70-0.30 (-0.19%)
As of 10:01AM CEST. Market open.

ALK-Abelló A/S

Bøge Allé 6-8
Horsholm 2970
45 45 74 75 76

Full-time employees2,828

Key executives

NameTitlePayExercisedYear born
Mr. Claus Steensen SoljeExecutive VP, CFO & Member of Management Board14.12MN/A1972
Mr. Søren Daniel NiegelExecutive VP of Commercial Operations & Member of Management Board5.33MN/A1971
Dr. Henriette MersebachExecutive VP Research & Development & Member of Management Board6.16MN/A1971
Ms. Katja Barnkob ThalundProject Director of Global CMC Development & Employee-elected Director350kN/A1969
Ms. Lise Lund MaerkedahlProject Director of Global Research & Employee-elected Director270kN/A1967
Mr. Peter HallingPresident & CEON/AN/A1977
Mr. Per PlotnikofVP of Corporate Communications, Investor Relations & Strategic Planning and Head of IRN/AN/AN/A
Prof. Hendrik Kees Kam Nolte M.D., Ph.D.Senior Vice President of Research & Development - North America and International MarketsN/AN/AN/A
Mr. Christian G. HoughtonHead of Product SupplyN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.


ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Corporate governance

ALK-Abelló A/S’s ISS governance QualityScore as of 1 May 2024 is 5. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 9; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.